Anti-cancer study required

The European Commission's, Joint Research Centre, Institute for Health and Consumer Protection, Validation of Biomedical Testing Method (ECVAM) has opened to tender a study contract on 'Induction of conformational changes in p53 mutants and modulation of sensitivity to selecti...

The European Commission's, Joint Research Centre, Institute for Health and Consumer Protection, Validation of Biomedical Testing Method (ECVAM) has opened to tender a study contract on 'Induction of conformational changes in p53 mutants and modulation of sensitivity to selective anti-cancer drugs'.

ECVAM's goal is to promote the scientific and regulatory acceptance of alternative methods which are of importance to the biosciences and which reduce, refine or replace the use of laboratory animals. Haematoxicology and anti-cancer drugs are areas of interest to ECVAM.

The aim of the study subject to this call for tender is to develop an in vitro endpoint and to evaluate the potency of new anti-cancer drugs.
For further information, please contact:

European Commission
Joint Research Centre
Institute for Health and Consumer Protection
Validation of Biomedical Testing Method Unit (ECVAM)
Mrs. C. Dal Molin
TP 580, Via Enrico Fermi1
I-21020
Ispra (VA)
Fax [phone]